These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 1497685)

  • 21. Steady state pharmacokinetics of conventional versus controlled-release carbamazepine in patients with epilepsy.
    Bonneton J; Iliadis A; Genton P; Dravet C; Viallat D; Mesdjian E
    Epilepsy Res; 1993 Mar; 14(3):257-63. PubMed ID: 8504796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple-dose pharmacokinetic study with a slow-release carbamazepine preparation.
    Reunanen M; Heinonen E; Anttila M; Järvensivu P; Lehto H; Hokkanen E
    Epilepsy Res; 1990 Jul; 6(2):126-33. PubMed ID: 2387286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diurnal variation of carbamazepine and carbamazepine-10,11-epoxide in plasma and saliva in children with epilepsy: a comparison between conventional and slow-release formulations.
    Eeg-Olofsson O; Nilsson HL; Tonnby B; Arvidsson J; Grahn PA; Gylje H; Larsson C; Norén L
    J Child Neurol; 1990 Apr; 5(2):159-65. PubMed ID: 2111837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical monitoring during carbamazepine slow-release, once-daily monotherapy.
    Stefan H; Schäfer H; Kuhnen C; Schneider S
    Epilepsia; 1988; 29(5):571-7. PubMed ID: 3137020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative bioavailability and steady state fluctuations of Tegretol commercial and carbamazepine OROS tablets in adult and pediatric epileptic patients.
    Thakker KM; Mangat S; Garnett WR; Levy RH; Kochak GM
    Biopharm Drug Dispos; 1992 Nov; 13(8):559-69. PubMed ID: 1421050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of epilepsy in mentally retarded patients with a slow-release carbamazepine preparation.
    Kaski M; Heinonen E; Sivenius J; Tuominen J; Anttila M
    J Ment Defic Res; 1991 Jun; 35 ( Pt 3)():231-9. PubMed ID: 1920391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monotherapy with conventional and controlled-release carbamazepine: a double-blind, double-dummy comparison in epileptic patients.
    McKee PJ; Blacklaw J; Butler E; Gillham RA; Brodie MJ
    Br J Clin Pharmacol; 1991 Jul; 32(1):99-104. PubMed ID: 1888646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fluctuations of carbamazepine concentrations during the day for two slow-release preparations.
    May T; Rambeck B
    Ther Drug Monit; 1989; 11(1):21-4. PubMed ID: 2911848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduction of dosing frequency of carbamazepine with a slow-release preparation.
    Sivenius J; Heinonen E; Lehto H; Järvensivu P; Anttila M; Ylinen A; Riekkinen P
    Epilepsy Res; 1988; 2(1):32-6. PubMed ID: 3197677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The importance of individual pharmacokinetic data for treatment of epilepsy with carbamazepine.
    Diehl LW; Müller-Oerlinghausen B; Riedel E
    Int J Clin Pharmacol Biopharm; 1976 Sep; 14(2):144-8. PubMed ID: 1002351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carbamazepine (CBZ) controlled release compared with conventional CBZ: a controlled study of attention and vigilance in children with epilepsy.
    Pieters MS; Jennekens-Schinkel A; Stijnen T; Edelbroek PM; Brouwer OF; Liauw L; Heyer A; Lanser JB; Peters AC
    Epilepsia; 1992; 33(6):1137-44. PubMed ID: 1464276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic comparison of two carbamazepine slow-release formulations.
    Jensen PK; Møller A; Gram L; Jensen NO; Dam M
    Acta Neurol Scand; 1990 Aug; 82(2):135-7. PubMed ID: 2256443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circadian carbamazepine toxicity.
    Haefeli WE; Meyer PG; Lüscher TF
    Epilepsia; 1994; 35(2):400-2. PubMed ID: 8156964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of the bioavailability of two carbamazepine preparations (200 and 400 mg tablets).
    Monaco F; Porcella V
    J Int Med Res; 1984; 12(2):108-13. PubMed ID: 6724125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Slow release carbamazepine in treatment of poorly controlled seizures.
    Ryan SW; Forsythe I; Hartley R; Haworth M; Bowmer CJ
    Arch Dis Child; 1990 Sep; 65(9):930-5. PubMed ID: 2221963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Comparative open trial of carbamazepine and slow-release carbamazepine in epilepsy in adults].
    Remy C
    Presse Med; 1990 Mar; 19(11):511-3. PubMed ID: 2138749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic evaluation of sustained release formulations of antiepileptic drugs. Clinical implications.
    Bialer M
    Clin Pharmacokinet; 1992 Jan; 22(1):11-21. PubMed ID: 1559305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Controlled release carbamazepine: cognitive side effects in patients with epilepsy.
    Aldenkamp AP; Alpherts WC; Moerland MC; Ottevanger N; Van Parys JA
    Epilepsia; 1987; 28(5):507-14. PubMed ID: 3653052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A bioequivalence study on retarded formulations of carbamazepine tablets.
    Scheuch E; Hoffmann C; Franke G; Rabending G; Zschiesche M; Siegmund W
    Int J Clin Pharmacol Ther Toxicol; 1992 Nov; 30(11):486-7. PubMed ID: 1490797
    [No Abstract]   [Full Text] [Related]  

  • 40. Dissolution and relative bioavailability of two carbamazepine preparations for children with epilepsy.
    Hartley R; Aleksandrowicz J; Bowmer CJ; Cawood A; Forsythe WI
    J Pharm Pharmacol; 1991 Feb; 43(2):117-9. PubMed ID: 1672895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.